A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies(NCT06634589)

BGB-16673 104

This trial is Coming soon
Registration number NCT06634589

Program & service

This trial is being run with the Cancer service, and as part of the Haematology program.

Trial phase

Phase 1

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Dr Maciej Tatarczuch

More information

To find out more about this clinical trial, please review full details on the ANZCTR website.

View on ANZCTR

If you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.